Amarantus BioSciences (OTCQB:AMBS) is developing a Lymphocyte Proliferation (LymPro) Blood Test for the diagnosis of Alzheimer's Disease. The company acquired the test from privately-held Memory Dx, LLC, in December 2012. The inventors of the test, Dr. Thomas Arendt and Dr. Jens Stieler of the University of Leipzig, Germany, had previously published data and the mechanism of action for LymPro in NeuroReport. We note that LymPro has completed two Phase I clinical studies in over 160 patients, showing 98% sensitivity and 96% specificity for Alzheimer's disease diagnosis.
The next step in the clinical development of LymPro is to establish the analytical performance of the assay in an outsourced GLP laboratory, as well as to conduct small clinical performance studies...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|